WO2006094756A3 - Varicella zoster virus vaccine - Google Patents

Varicella zoster virus vaccine Download PDF

Info

Publication number
WO2006094756A3
WO2006094756A3 PCT/EP2006/002070 EP2006002070W WO2006094756A3 WO 2006094756 A3 WO2006094756 A3 WO 2006094756A3 EP 2006002070 W EP2006002070 W EP 2006002070W WO 2006094756 A3 WO2006094756 A3 WO 2006094756A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus vaccine
zoster virus
varicella zoster
vzv
adjuvant
Prior art date
Application number
PCT/EP2006/002070
Other languages
French (fr)
Other versions
WO2006094756A2 (en
Inventor
Emmanuel Jules Hanon
Jean Stephenne
Original Assignee
Glaxosmithkline Biolog Sa
Emmanuel Jules Hanon
Jean Stephenne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34430592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006094756(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to MX2007010626A priority Critical patent/MX2007010626A/en
Priority to US11/817,175 priority patent/US20080171079A1/en
Priority to SI200631890T priority patent/SI1858917T1/en
Priority to EA200701632A priority patent/EA011884B1/en
Priority to PL06707446T priority patent/PL1858917T3/en
Priority to EP20060707446 priority patent/EP1858917B8/en
Priority to CA2600905A priority patent/CA2600905C/en
Priority to DK06707446.8T priority patent/DK1858917T3/en
Priority to JP2007557447A priority patent/JP5420842B2/en
Priority to KR1020077022672A priority patent/KR101357204B1/en
Priority to KR1020137034242A priority patent/KR20140006115A/en
Priority to NZ561075A priority patent/NZ561075A/en
Priority to MX2012004471A priority patent/MX346865B/en
Priority to AU2006222225A priority patent/AU2006222225B2/en
Application filed by Glaxosmithkline Biolog Sa, Emmanuel Jules Hanon, Jean Stephenne filed Critical Glaxosmithkline Biolog Sa
Priority to BRPI0607840-0A priority patent/BRPI0607840B1/en
Priority to ES06707446.8T priority patent/ES2532803T3/en
Priority to CN2006800152455A priority patent/CN101189254B/en
Priority to UAA200709537A priority patent/UA94900C2/en
Publication of WO2006094756A2 publication Critical patent/WO2006094756A2/en
Publication of WO2006094756A3 publication Critical patent/WO2006094756A3/en
Priority to IL185442A priority patent/IL185442A/en
Priority to NO20074392A priority patent/NO341841B1/en
Priority to HK08102085.4A priority patent/HK1111427A1/en
Priority to US12/784,296 priority patent/US20110045059A1/en
Priority to US12/986,928 priority patent/US7939084B1/en
Priority to HRP20150142TT priority patent/HRP20150142T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Use of an immunogenic composition comprising VZV gE, or immunogenic fragment thereof, and a TH-1 adjuvant in the preparation of a medicament for the prevention or amelioration of shingles and/or post herpetic neuralgia. Compositions comprising a truncated VZV gE antigen and an adjuvant containing QS21, cholesterol and 3D MPL are also claimed.
PCT/EP2006/002070 2005-03-03 2006-03-01 Varicella zoster virus vaccine WO2006094756A2 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
US11/817,175 US20080171079A1 (en) 2005-03-03 2006-03-01 Vaccine
AU2006222225A AU2006222225B2 (en) 2005-03-03 2006-03-01 Varicella zoster virus vaccine
MX2012004471A MX346865B (en) 2005-03-03 2006-03-01 Varicella zoster virus vaccine.
EA200701632A EA011884B1 (en) 2005-03-03 2006-03-01 Varicella zoster virus vaccine
PL06707446T PL1858917T3 (en) 2005-03-03 2006-03-01 Varicella zoster virus vaccine
EP20060707446 EP1858917B8 (en) 2005-03-03 2006-03-01 Varicella zoster virus vaccine
CA2600905A CA2600905C (en) 2005-03-03 2006-03-01 Vaccine
DK06707446.8T DK1858917T3 (en) 2005-03-03 2006-03-01 Varicella-zoster virus vaccine
JP2007557447A JP5420842B2 (en) 2005-03-03 2006-03-01 Blister-herpes zoster virus vaccine
KR1020077022672A KR101357204B1 (en) 2005-03-03 2006-03-01 Varicella zoster virus vaccine
KR1020137034242A KR20140006115A (en) 2005-03-03 2006-03-01 Varicella zoster virus vaccine
NZ561075A NZ561075A (en) 2005-03-03 2006-03-01 Varicella zoster virus vaccine
SI200631890T SI1858917T1 (en) 2005-03-03 2006-03-01 Varicella zoster virus vaccine
MX2007010626A MX2007010626A (en) 2005-03-03 2006-03-01 Varicella zoster virus vaccine.
UAA200709537A UA94900C2 (en) 2005-03-03 2006-03-01 Vaccine
BRPI0607840-0A BRPI0607840B1 (en) 2005-03-03 2006-03-01 USE OF AN IMMUNOGENIC COMPOSITION AND KIT
ES06707446.8T ES2532803T3 (en) 2005-03-03 2006-03-01 Varicella-zoster virus vaccine
CN2006800152455A CN101189254B (en) 2005-03-03 2006-03-01 Vaccine
IL185442A IL185442A (en) 2005-03-03 2007-08-22 Immunogenic composition consisting of a varicella zoster virus ge truncated antigen for the prevention of shingles and/or post herpetic neuralgia and its preparation
NO20074392A NO341841B1 (en) 2005-03-03 2007-08-29 Use of an immunogenic composition comprising VZV gE antigen, immunogenic composition and vaccine
HK08102085.4A HK1111427A1 (en) 2005-03-03 2008-02-25 Varicella zoster virus vaccine
US12/784,296 US20110045059A1 (en) 2005-03-03 2010-05-20 Vaccine against varicella zoster virus
US12/986,928 US7939084B1 (en) 2005-03-03 2011-01-07 Vaccine against varicella zoster virus
HRP20150142TT HRP20150142T1 (en) 2005-03-03 2015-02-04 Varicella zoster virus vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0504436.7A GB0504436D0 (en) 2005-03-03 2005-03-03 Vaccine
GB0504436.7 2005-03-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/817,175 A-371-Of-International US20080171079A1 (en) 2005-03-03 2006-03-01 Vaccine
US12/784,296 Continuation US20110045059A1 (en) 2005-03-03 2010-05-20 Vaccine against varicella zoster virus

Publications (2)

Publication Number Publication Date
WO2006094756A2 WO2006094756A2 (en) 2006-09-14
WO2006094756A3 true WO2006094756A3 (en) 2007-02-15

Family

ID=34430592

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/002070 WO2006094756A2 (en) 2005-03-03 2006-03-01 Varicella zoster virus vaccine

Country Status (35)

Country Link
US (3) US20080171079A1 (en)
EP (4) EP2281830B1 (en)
JP (2) JP5420842B2 (en)
KR (2) KR20140006115A (en)
CN (2) CN103028113B (en)
AR (2) AR052498A1 (en)
AU (1) AU2006222225B2 (en)
BR (1) BRPI0607840B1 (en)
CA (2) CA2600905C (en)
CY (5) CY1116108T1 (en)
DK (4) DK2281831T3 (en)
EA (1) EA011884B1 (en)
ES (4) ES2675055T3 (en)
GB (1) GB0504436D0 (en)
HK (1) HK1111427A1 (en)
HR (4) HRP20150142T1 (en)
HU (4) HUE038468T2 (en)
IL (1) IL185442A (en)
LT (4) LT2301955T (en)
LU (1) LUC00087I2 (en)
MA (1) MA29714B1 (en)
MX (2) MX2007010626A (en)
MY (1) MY148464A (en)
NL (1) NL300951I2 (en)
NO (1) NO341841B1 (en)
NZ (1) NZ561075A (en)
PE (2) PE20061287A1 (en)
PL (4) PL2281831T3 (en)
PT (4) PT2301955T (en)
SI (4) SI1858917T1 (en)
TR (2) TR201809397T4 (en)
TW (1) TWI403517B (en)
UA (1) UA94900C2 (en)
WO (1) WO2006094756A2 (en)
ZA (1) ZA200707144B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845925B2 (en) 2010-07-06 2023-12-19 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
US11850305B2 (en) 2010-07-06 2023-12-26 Glaxosmithkline Biologicals Sa Method of making lipid formulations with RNA encoding immunogens

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (en) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
CA2729011A1 (en) * 2007-07-19 2009-01-22 Novavax, Inc. Varicella zoster virus-virus like particles (vlps) and antigens
FR2952825B1 (en) 2009-11-24 2012-05-25 Goaster Jacqueline Le USE OF A VZV / HSV3 VIRUS VACCINE FOR TREATING HERPETIC INFECTIONS WITH HSV1 VIRUS AND / OR HSV2 VIRUS
LT3243526T (en) 2010-07-06 2020-02-10 Glaxosmithkline Biologicals S.A. Delivery of rna to trigger multiple immune pathways
UA112970C2 (en) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. INITIATED WINDOW ISLAND VIRUS, METHOD OF ITS RECEIVING AND APPLICATION
SI2611461T1 (en) 2010-08-31 2022-08-31 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of immunogen-encoding rna
AU2011316707A1 (en) 2010-10-11 2013-05-09 Novartis Ag Antigen delivery platforms
ES2656050T3 (en) 2011-07-06 2018-02-22 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN105530953A (en) * 2013-10-03 2016-04-27 日东电工株式会社 Injectable vaccine composition
JP6499420B2 (en) * 2014-11-13 2019-04-10 公益財団法人ヒューマンサイエンス振興財団 Vaccines and infection protection kits
BR112017012647A2 (en) * 2014-12-18 2018-01-09 Glaxosmithkline Biologicals Sa immunogenic composition, method for protection against or prevention of herpes zoster (hz) and / or postherpetic neuralgia, and method for protection against, prevention or reduction of the incidence of herpes zoster and / or postherpetic neuralgia.
BE1022523B1 (en) * 2014-12-18 2016-05-20 Glaxosmithkline Biologicals Sa VACCINATION
EP4349404A2 (en) 2015-10-22 2024-04-10 ModernaTX, Inc. Respiratory virus vaccines
CN117731769A (en) * 2015-10-22 2024-03-22 摩登纳特斯有限公司 Nucleic acid vaccine for Varicella Zoster Virus (VZV)
IL293848A (en) 2015-11-06 2022-08-01 Adjuvance Tech Inc Triterpene saponin analogues, methods of producing same, compositions comprising same and uses thereof
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. Influenza vaccine
KR102028463B1 (en) * 2016-11-25 2019-10-04 재단법인 목암생명과학연구소 Varicella Zoster Virus Vaccines
WO2018097642A1 (en) * 2016-11-25 2018-05-31 재단법인 목암생명과학연구소 Varicella zoster virus vaccine
CN107022559A (en) * 2016-12-08 2017-08-08 长春祈健生物制品有限公司 A kind of preparation method of varicellazoster virus glycoprotein E extracellular region protein
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CA3048608C (en) * 2016-12-26 2021-11-23 Mogam Institute For Biomedical Research Herpes zoster vaccine composition
CN108727503A (en) * 2017-04-18 2018-11-02 武汉博沃生物科技有限公司 VZV recombinates gE- flagellum plain fusion proteins and its preparation method and application
IL292991A (en) * 2017-04-25 2022-07-01 Adjuvance Tech Inc Triterpene saponin analogues
US20200164065A1 (en) * 2017-04-25 2020-05-28 Adjuvance Technologies, Inc. Triterpene saponin analogues
WO2018198085A1 (en) 2017-04-28 2018-11-01 Glaxosmithkline Biologicals Sa Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
BR112019025193A2 (en) 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. METHODS OF MANUFACTURING A LIPOSOMAL ADJUVANT, MANUFACTURING A LIPOSOMAL CONCENTRATE, FOR THE PREPARATION OF AN IMMUNOGENIC COMPOSITION WITH ADJUVANT AND FOR THE PREPARATION OF A SOLUTION, LIPOSOMAL ADJUVANT, IMMUNOGENOUS COMPOUND, WITH SOLUTION,
CN111212846B (en) 2017-10-16 2023-05-26 佐剂技术公司 Triterpene saponin analogues
EP3717001A1 (en) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Saponin purification
CN108315344A (en) * 2018-02-14 2018-07-24 武汉博沃生物科技有限公司 VZV glycoprotein E genes expression vector and its restructuring yeast strains and application
KR102337922B1 (en) 2018-04-19 2021-12-09 가천대학교 산학협력단 Pharmaceutical composition for inhibiting varicella-zoster virus comprising compounds isolated from Elaeocarpus sylvestris extract as an active ingradient
KR20190121956A (en) 2018-04-19 2019-10-29 가천대학교 산학협력단 Pharmaceutical composition for inhibiting varicella-zoster virus comprising compounds isolated from Elaeocarpus sylvestris extract as an active ingradient
CN112189017A (en) * 2018-05-23 2021-01-05 财团法人牧岩生命科学研究所 Antigenic variants of varicella zoster virus and uses thereof
MX2021001479A (en) 2018-08-07 2021-04-28 Glaxosmithkline Biologicals Sa Processes and vaccines.
CN108992667A (en) * 2018-08-09 2018-12-14 安徽智飞龙科马生物制药有限公司 A kind of shingles zoster vaccine and preparation method thereof, application
KR102270048B1 (en) * 2020-07-10 2021-06-28 주식회사 녹십자 Method for production of surface protein antigen of varicella zoster virus
CN113164586B (en) * 2018-09-27 2024-04-16 武汉博沃生物科技有限公司 Immune composition and preparation method and application thereof
EP3886901A1 (en) 2018-11-29 2021-10-06 GlaxoSmithKline Biologicals S.A. Methods for manufacturing an adjuvant
CN109602901B (en) * 2019-01-08 2022-05-27 成都迈科康生物科技有限公司 Herpes zoster virus vaccine and preparation method and application thereof
BR112021024363A2 (en) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Saponin purification
CN112142828B (en) * 2019-06-28 2022-02-01 怡道生物科技(苏州)有限公司 gE gene and vector for expressing the gene
CN112972670B (en) * 2019-12-13 2023-12-19 远大赛威信生命科学(南京)有限公司 Immunostimulatory compositions and uses thereof
US20230110839A1 (en) * 2020-02-28 2023-04-13 Celltrion Inc. Varicella zoster virus fusion protein and immunogenic composition comprising same
AU2021321944A1 (en) 2020-08-07 2023-04-06 Access To Advanced Health Institute Purified saponins and chromatographic process for purification of same
WO2022055176A1 (en) * 2020-09-11 2022-03-17 주식회사 유바이오로직스 Vaccine composition for chickenpox or varicella zoster and method of using same
RU2750818C1 (en) * 2020-11-19 2021-07-05 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова Viral strain for obtaining attenuated live culture vaccine for prevention and treatment of herpes zoster for adult population
WO2023056912A1 (en) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for vzv
WO2023064612A2 (en) 2021-10-15 2023-04-20 BioNTech SE Pharmaceutical compositions for delivery of viral antigens and related methods
WO2023096963A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
CN116350770A (en) * 2021-12-28 2023-06-30 成都迈科康生物科技有限公司 Herpes zoster vaccine preparation and preparation method thereof
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033739A1 (en) * 1995-04-25 1996-10-31 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
WO2000043527A1 (en) * 1999-01-20 2000-07-27 Smithkline Beecham Biologicals S.A. Varicella-zoster virus vaccines
WO2002032450A2 (en) * 2000-10-18 2002-04-25 Glaxosmithkline Biologicals S.A. Vaccines

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5341202B2 (en) 1974-03-12 1978-11-01
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE69017769T2 (en) 1989-06-27 1995-07-13 Smithkline Beecham Biolog Links.
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
JP3723231B2 (en) 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト Adjuvant
SG49909A1 (en) 1992-06-25 1998-06-15 Smithkline Beecham Biolog Vaccine composition containing adjuvants
CA2139515C (en) 1992-07-17 2008-12-23 Gary B. Calandra Method for preventing zoster or alleviating varicella related post-herpetic neuralgia
DE69405551T3 (en) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-DEAZYLATED MONOPHOSPHORYL LIPID A-CONTAINING VACCINE COMPOSITIONS
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
NZ306653A (en) * 1995-03-23 1999-03-29 Immunex Corp Isolated dna il-17 receptors
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
KR0177323B1 (en) * 1996-02-16 1999-04-01 성재갑 Human diploid lung cells useful for virus vaccine production and method for preparing chickenpox vaccine using the same
JP5019494B2 (en) 1997-04-01 2012-09-05 コリクサ コーポレーション Aqueous immune adjuvant composition of monophosphoryl lipid A
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033739A1 (en) * 1995-04-25 1996-10-31 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
WO2000043527A1 (en) * 1999-01-20 2000-07-27 Smithkline Beecham Biologicals S.A. Varicella-zoster virus vaccines
WO2002032450A2 (en) * 2000-10-18 2002-04-25 Glaxosmithkline Biologicals S.A. Vaccines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JACQUET A ET AL: "Immunogenicity of a recombinant varicella-zoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 20, no. 11-12, 22 February 2002 (2002-02-22), pages 1593 - 1602, XP004340381, ISSN: 0264-410X *
VAFAI A: "Boosting immune response with a candidate varicella-zoster virus glycoprotein subunit vaccine", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 13, no. 14, October 1995 (1995-10-01), pages 1336 - 1338, XP004057437, ISSN: 0264-410X *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845925B2 (en) 2010-07-06 2023-12-19 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
US11850305B2 (en) 2010-07-06 2023-12-26 Glaxosmithkline Biologicals Sa Method of making lipid formulations with RNA encoding immunogens
US11851660B2 (en) 2010-07-06 2023-12-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA

Also Published As

Publication number Publication date
GB0504436D0 (en) 2005-04-06
DK2281830T3 (en) 2017-03-20
EA200701632A1 (en) 2008-02-28
CN101189254A (en) 2008-05-28
MA29714B1 (en) 2008-09-01
HRP20150142T1 (en) 2015-05-22
PL2281831T3 (en) 2018-08-31
LT2281830T (en) 2017-02-10
LUC00087I2 (en) 2018-11-26
HRP20180988T1 (en) 2018-08-10
ES2618037T3 (en) 2017-06-20
ES2675054T3 (en) 2018-07-06
EP2281830B1 (en) 2016-12-21
PL1858917T3 (en) 2015-05-29
CY2018025I2 (en) 2018-12-12
US20080171079A1 (en) 2008-07-17
JP5840167B2 (en) 2016-01-06
PT2281831T (en) 2018-06-15
ES2532803T3 (en) 2015-03-31
HUE038468T2 (en) 2018-10-29
NO20074392L (en) 2007-11-27
KR20070110413A (en) 2007-11-16
EP2301955A3 (en) 2011-11-16
TR201809397T4 (en) 2018-07-23
PE20100658A1 (en) 2010-10-23
PL2301955T3 (en) 2018-08-31
NL300951I2 (en) 2020-08-31
CN103028113A (en) 2013-04-10
EP2281831A3 (en) 2011-11-16
EP2281830A2 (en) 2011-02-09
BRPI0607840A2 (en) 2009-06-13
EP1858917B1 (en) 2014-12-24
ZA200707144B (en) 2009-11-25
WO2006094756A2 (en) 2006-09-14
EP2301955A2 (en) 2011-03-30
DK2301955T3 (en) 2018-06-14
NZ561075A (en) 2009-06-26
TR201809393T4 (en) 2018-07-23
BRPI0607840B1 (en) 2021-06-29
LT2281831T (en) 2018-07-10
SI2281831T1 (en) 2018-07-31
NL300951I1 (en) 2018-09-26
US20110104260A1 (en) 2011-05-05
TWI403517B (en) 2013-08-01
AR052498A1 (en) 2007-03-21
EP2281830A3 (en) 2012-01-25
CN103028113B (en) 2015-05-20
EP1858917A2 (en) 2007-11-28
PT2281830T (en) 2017-02-24
PT1858917E (en) 2015-02-24
SI2281830T1 (en) 2017-03-31
US20110045059A1 (en) 2011-02-24
CA2600905C (en) 2015-05-05
AU2006222225B2 (en) 2012-08-16
LT2301955T (en) 2018-07-10
JP5420842B2 (en) 2014-02-19
JP2013144710A (en) 2013-07-25
KR20140006115A (en) 2014-01-15
UA94900C2 (en) 2011-06-25
CY1120347T1 (en) 2018-12-12
NO341841B1 (en) 2018-02-05
US7939084B1 (en) 2011-05-10
EP1858917B8 (en) 2015-05-06
ES2675055T3 (en) 2018-07-06
MY148464A (en) 2013-04-30
SI1858917T1 (en) 2015-03-31
IL185442A (en) 2013-07-31
HUS1800038I1 (en) 2018-10-29
CA2882255A1 (en) 2006-09-14
CY1118629T1 (en) 2017-07-12
HK1111427A1 (en) 2008-08-08
HUE038467T2 (en) 2018-10-29
DK2281831T3 (en) 2018-06-14
AR107285A2 (en) 2018-04-18
EP2281831A2 (en) 2011-02-09
TW200643028A (en) 2006-12-16
LTPA2018012I1 (en) 2018-11-12
PL2281830T3 (en) 2017-06-30
EP2301955B1 (en) 2018-04-18
HUE032544T2 (en) 2017-10-30
IL185442A0 (en) 2008-01-06
CN101189254B (en) 2013-05-22
PT2301955T (en) 2018-06-18
HRP20180989T1 (en) 2018-08-10
KR101357204B1 (en) 2014-02-06
JP2008531637A (en) 2008-08-14
MX346865B (en) 2017-04-04
HRP20170081T1 (en) 2017-03-24
LTC2281831I2 (en) 2020-08-25
PE20061287A1 (en) 2006-12-07
DK1858917T3 (en) 2015-02-02
MX2007010626A (en) 2007-10-16
SI2301955T1 (en) 2018-07-31
CA2600905A1 (en) 2006-09-14
CY1121211T1 (en) 2020-05-29
EP2281831B1 (en) 2018-04-18
EA011884B1 (en) 2009-06-30
AU2006222225A1 (en) 2006-09-14
CA2882255C (en) 2018-03-27
CY2018025I1 (en) 2018-12-12
CY1116108T1 (en) 2017-02-08

Similar Documents

Publication Publication Date Title
WO2006094756A3 (en) Varicella zoster virus vaccine
WO2007095976A3 (en) Adjuvant in the form of a lipid-modified nucleic acid
BRPI0621181A8 (en) IMMUNOGENIC SUBSTANCES THAT COMPRISE AN ADJUVANT BASED ON POLYINOSINIC ACID - POLYCYTYDYLIC ACID
WO2007024941A3 (en) Polyvalent vaccine
WO2006076003A3 (en) Vaccinia virus strains
WO2006071989A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
SG170127A1 (en) Vaccine compositions comprising a saponin adjuvant
WO2001022992A3 (en) Influenza vaccine
WO2007052155A3 (en) Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
EP2246067A3 (en) Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
WO2008096831A1 (en) Therapeutic agent for cancer
WO2009085025A3 (en) System and method for sparql-query processing using parametrized-sparql-query in dbms-based systems
WO2009135199A3 (en) Vaccine compositions and methods
WO2009115917A3 (en) Improvements in preparation of influenza virus vaccine antigens
WO2010012069A8 (en) Multivalent vaccines based on papaya mosaic virus and uses thereof
WO2006087563A3 (en) Adjuvant composition comprising aluminium phosphate and 3d-mpl
WO2005121378A3 (en) Methods and compositions for vaccination
WO2008008541A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
WO2006044864A3 (en) Vaccine adjuvant
WO2008133645A3 (en) Combination vaccine for prevention of tularemia
WO2004101737A3 (en) A novel adjuvant capable of specifically activating the adaptive immune response
WO2009129498A3 (en) Substance p and analogs thereof as a cancer immunogenic composition adjuvant
WO2008076157A3 (en) Modified vaccinia ankara virus vaccine
WO2008097970A3 (en) Canine influenza immunogenic compositions and methods of use thereof
曲欣欣 VIEWING THE WORLD

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 185442

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006222225

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 11817175

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 561075

Country of ref document: NZ

Ref document number: MX/a/2007/010626

Country of ref document: MX

Ref document number: 2007557447

Country of ref document: JP

Ref document number: 2600905

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12007501863

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 3310/KOLNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2006222225

Country of ref document: AU

Date of ref document: 20060301

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006222225

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006707446

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 07101632

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: DZP2007000616

Country of ref document: DZ

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWE Wipo information: entry into national phase

Ref document number: 200701632

Country of ref document: EA

Ref document number: 1020077022672

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200680015245.5

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006707446

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0607840

Country of ref document: BR

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 1020137034242

Country of ref document: KR